OBLN - オバロン・セラピュ―ティクス (Obalon Therapeutics Inc.) オバロン・セラピュ―ティクス

 OBLNのチャート


 OBLNの企業情報

symbol OBLN
会社名 Obalon Therapeutics Inc (オバロン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 オバロン・セラピューティクス(Obalon Therapeutics Inc)は体重減少を促進することによって肥満を治療する医療機器の開発・商品化に集中する商業ステージの医療機器会社である。同社の製品オーバロン・バルーン・システムは肥満患者の体重減少を促進する飲み込めるガス充填胃内バルーンである。オーバロン・バルーン・システムは中強度食品・行動調整プログラムの付属物として使用される。全部のバルーンは最初のバルーンの設置後6ヶ月で除去される。オーバロン・バルーン・システムは患者の解剖変更または手術要求なしに患者・医者に可逆的・繰り返し可能な体重減少ソリューションを提供することを目的とする。同社はスマート・トライアルと称される米国ピボタル臨床試験の結果に基づくオーバロン・バルーン・システムで製造販売承認(PMA)を取得した。   オバロン・セラピュ―ティクスは米国の医療機器メ―カ―。主に肥満解消を目的とした医療装置を開発・製造・販売する。同社の「オバロン・バル―ン・システム」は、ガス入りカプセルを飲み下すことにより胃内容積を占有し、食欲減退を促し体重減少に導く、患者への負担の少ない治療方法である。本社はカリフォルニア州カ―ルスバッド。   Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then remotely inflated. The company was founded on January 2, 2008 and is headquartered in Carlsbad, CA.
本社所在地 5421 Avenida Encinas Suite F Carlsbad CA 92008 USA
代表者氏名 Kim P Kamdar キム・P・カムダール
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 858-480-2400
設立年月日 39448
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 137人
url www.obalon.com
nasdaq_url https://www.nasdaq.com/symbol/obln
adr_tso
EBITDA EBITDA(百万ドル) -40.19200
終値(lastsale) 2.14
時価総額(marketcap) 49830349.4
時価総額 時価総額(百万ドル) 45.87186
売上高 売上高(百万ドル) 10.55700
企業価値(EV) 企業価値(EV)(百万ドル) 30.60786
当期純利益 当期純利益(百万ドル) -41.16900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Obalon Therapeutics Inc revenues increased 19% to $4.1M. Net loss increased 41% to $21.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling general and administrative - B increase of 39% to $15.2M (expense) Stock-based Compensation in SGA increase from $829K to $2M (expense).

 OBLNのテクニカル分析


 OBLNのニュース

   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?  2020/01/24 16:30:10 Zacks Investment Research
Is (OBLN) Outperforming Other Medical Stocks This Year?
   Obalon Therapeutics Inc (NASDAQ:OBLN) CEO Buys $107,900.00 in Stock  2019/11/17 12:38:32 Modern Readers
Obalon Therapeutics Inc (NASDAQ:OBLN) CEO William J. Plovanic acquired 65,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $1.66 per share, with a total value of $107,900.00. Following the completion of the purchase, the chief executive officer now owns 106,806 shares of the […]
   OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2019/11/01 14:30:29 Zacks Investment Research
OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?  2020/01/24 16:30:10 Zacks Investment Research
Is (OBLN) Outperforming Other Medical Stocks This Year?
   Obalon Therapeutics Inc (NASDAQ:OBLN) CEO Buys $107,900.00 in Stock  2019/11/17 12:38:32 Modern Readers
Obalon Therapeutics Inc (NASDAQ:OBLN) CEO William J. Plovanic acquired 65,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $1.66 per share, with a total value of $107,900.00. Following the completion of the purchase, the chief executive officer now owns 106,806 shares of the […]
   OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2019/11/01 14:30:29 Zacks Investment Research
OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?  2020/01/24 16:30:10 Zacks Investment Research
Is (OBLN) Outperforming Other Medical Stocks This Year?
   Obalon Therapeutics Inc (NASDAQ:OBLN) CEO Buys $107,900.00 in Stock  2019/11/17 12:38:32 Modern Readers
Obalon Therapeutics Inc (NASDAQ:OBLN) CEO William J. Plovanic acquired 65,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $1.66 per share, with a total value of $107,900.00. Following the completion of the purchase, the chief executive officer now owns 106,806 shares of the […]
   OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2019/11/01 14:30:29 Zacks Investment Research
OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 オバロン・セラピュ―ティクス OBLN Obalon Therapeutics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)